A prospective phase II study of raltitrexed combined with S‐1 as salvage treatment for patients with refractory metastatic colorectal cancer

AIM: A third‐line chemotherapy regimen for metastatic colorectal cancer (mCRC) is not available in China. Studies have shown that raltitrexed or S‐1 has no complete cross‐resistance with fluorouracil (5‐FU). In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed com...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Mingzhu, Yang, Yue, Zhu, Xiaodong, Chen, Zhiyu, Zhang, Wen, Wang, Chenchen, Zhang, Xiaowei, Qiu, Lixin, Zhang, Zhe, Zhao, Xiaoying, Li, Wenhua, Wang, Yusheng, Guo, Weijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290727/
https://www.ncbi.nlm.nih.gov/pubmed/33567129
http://dx.doi.org/10.1111/ajco.13511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290727/
https://www.ncbi.nlm.nih.gov/pubmed/33567129
http://dx.doi.org/10.1111/ajco.13511

Ejemplares similares